Differential modulation of human immunoglobulin isotype production by the neuropeptides substance P, NKA and NKB.
The modifying effects of tachykinins substance P, neurokinin A and neurokinin B on immunoglobulin production were analyzed in an in vitro culture system. Purified human T- and B-cells were stimulated with TGFbeta2 and IL-5 to induce preferential IgA production. Neuropeptides had the following effects. (1) The levels of IgA and IgG4 production were enhanced by IL-5 and TGFbeta2; IgA levels remained constant or were slightly augmented by neuropeptides, whereas IgG4 was further augmented. (2) IL-5 and TGFbeta2 did not alter IgG3 production, but neuropeptides stimulated secretion of this subclass. (3) IgG1 and IgM production were inhibited by IL-5 and TGFbeta2. This effect was prevented by neuropeptides. (4) Other isotypes including IgG2 and IgE remained unaffected. Except for IgM, these effects were blocked by specific receptor antagonists indicating specificity. The tachykinin receptor NK-1 mRNA was detected in B- and T-cells, whereas NK-3 mRNA was only present in T- and B-cell coculture following activation. Furthermore, neuropeptide effects depended on cytokine co-stimulation and the presence of T-cells. These results suggest that neuropeptides are potent modifiers of preferential IgA synthesis.
Braun
A
A
Department of Laboratory Medicine and Pathobiochemistry, Clinic of the Humboldt University, Berlin, Germany. armin.braun@charite.de
Wiebe
P
P
Pfeufer
A
A
Gessner
R
R
Renz
H
H
D001402:B-Lymphocytes / Q000737:chemistry / Q000166:cytology / Q000276:immunology; D002478:Cells, Cultured; D017931:DNA Primers; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes; D015870:Gene Expression / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D007073:Immunoglobulin E / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D007075:Immunoglobulin M / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D007136:Immunoglobulins / Q000032:analysis / Q000276:immunology* / Q000378:metabolism; D015848:Interleukin-5 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D009092:Mucous Membrane / Q000166:cytology / Q000276:immunology; D015213:Neuroimmunomodulation / Q000276:immunology*; D015288:Neurokinin A / Q000235:genetics / Q000276:immunology; D015287:Neurokinin B / Q000235:genetics / Q000276:immunology; D011043:Pokeweed Mitogens / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D018040:Receptors, Neurokinin-1 / Q000235:genetics / Q000276:immunology; D012680:Sensitivity and Specificity; D013373:Substance P / Q000276:immunology; D013601:T-Lymphocytes / Q000737:chemistry / Q000166:cytology / Q000276:immunology; D015320:Tachykinins / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000494:pharmacology
D017931:DNA Primers; D000939:Epitopes; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D015848:Interleukin-5; D011043:Pokeweed Mitogens; D012333:RNA, Messenger; D018040:Receptors, Neurokinin-1; D015320:Tachykinins; D016212:Transforming Growth Factor beta; D013373:Substance P; D007073:Immunoglobulin E; D015288:Neurokinin A; D015287:Neurokinin B